期刊文献+

HIF-1在卵巢黄体发育过程中对血管新生的调控作用 被引量:10

Regulatory Effects of HIF-1 on the Angiogenesis during Ovarian Luteal Development
原文传递
导出
摘要 在哺乳动物中,卵巢黄体(corpus luteum,CL)是由破裂排卵后的卵泡所形成的,也是血管增生比较激烈的地方。尤其是在卵巢黄体早期发育阶段,这种快速形成的致密毛细血管网可以确保产生激素的细胞获得氧气、营养和合成激素等所必要的前体,同时释放大量的激素用于早期妊娠的建立和维持。目前的研究已经表明,血管内皮生长因子(vascular endothelial growth factor,VEGF)作为重要的促血管生成因子,在卵巢黄体发育过程中对血管增生具有至关重要的调节作用,而VEGF作为转录因子HIF-1的下游靶基因,受缺氧诱导因子HIF-1信号通路的调控。该文一方面对卵巢黄体发育过程中VEGF依赖性血管增生的调控机制进行概述,另一方面就转录因子HIF-1对VEGF的转录激活调控机制进行系统阐述,从而揭示HIF-1对卵巢黄体发育过程中VEGF依赖性血管新生的调控作用,为进一步研究哺乳动物卵巢黄体发育过程中血管增生的分子调控机制提供坚实的理论基础。 In mammals, ovarian corpus luteum is formed from the ruptured follicle after ovulation, where the angiogenesis is much more intense. Especially in the early developmental stage of the corpus luteum, this rapid formation of a dense capillary network can ensure the cells, which produce hormones, to obtain oxygen, nutrients and the necessary precursors of synthetic hormones. At the same time, it can release a large number of hormones for establishing and maintaining early pregnancy. The current investigations have shown that vascular endothelial growth factor (VEGF), as an important angiogenic factor, plays a crucial regulatory role in angiogenesis during the development of corpus luteum, while as a downstream target gene of the transcription factor HIF-1 (hypoxia-induc- ible factor-1), VEGF is regulated by HIF-1 signaling pathway. In the present paper, we firstly overviewed the regu- latory mechanism of VEGF-dependent angiogenesis during the development of corpus luteum, and then described the regulation mechanism of transcription factor HIF-1 on the transcriptional activation of VEGF. All of these will reveal the regulatory role of HIF-1 in VEGF-dependent angiogenesis during the development of corpus luteum, which can provide a solid theoretical foundation for further studying the molecular mechanism of the angiogenic regulation during the development of corpus luteum in mammalian ovary.
出处 《中国细胞生物学学报》 CAS CSCD 北大核心 2012年第10期1042-1048,共7页 Chinese Journal of Cell Biology
基金 国家自然科学基金(No.31101032) 教育部博士点基金(No.20113503120002) 福建省自然科学基金(No.2011J01144) 福建省高层次人才引进项目(No.2010MIN114) 国家级生物学实验教学示范中心创新项目(No.2011LS017) 福建省教育厅杰出青年基金(No.AJ11041)资助项目~~
关键词 缺氧诱导因子 血管内皮生长因子 血管增生 黄体 hypoxia-inducible factor vascular endothelial growth factor angiogenesis corpus luteum
  • 相关文献

参考文献4

二级参考文献30

共引文献20

同被引文献82

  • 1Nastri C O, Ferriani R A, Rocha I A, et al. Ovarian hypers- tirnulation syndrome: pathophysiology and prevention [J]. J Assist Reprod Gen, 2010, 27(2-3): 121-128.
  • 2Rollene N L, Amols M H, Hudson S B, et al. Treatment ofo varian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist : a case series[J]. Fertility Sterility, 2009, 92(3):116915-116917.
  • 3Shaltout A, Shohyab A, Youssef M A. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles: A randomized controlled study[J]. Euro J Obstet Gynecol Reprod Biol, 2012, 165(2): 254-258.
  • 4Kalampokas T, Creatsas G, Kalampokas E. Cabergofine as treatment of ovarian hyperstimulation syndrome: a review[J]. GynecoI Endocrinol, 2013, 29(2): 98-100.
  • 5Ferraretti A P, Gianaroli L, Diotallevi I., et ai. Dopamine treatment for severe ovarian hyperstimulation syndrome [J]. Human Reprod , 1992, 7(2): 180-183.
  • 6Alvarez C, Marti Bonmati L, Novella-Maestre E, et al. Dopa- mine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction[J]. J Clin Endocrlnol Metabolism, 2007, 92(8): 2931-2937.
  • 7Vanrell J A, Balasch J. Prolactin in the evaluation of luteal phase in infertility[J]. Fertility Sterility, 1983, 39(1) : 30-33.
  • 8Alvarez C, Alonso-Muriel I, Garcia G, et al. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syn- drome in women undergoing assisted reproduction treatment: a pilot study[J]. HumanReprod, 2007, 22(12): 3210-3214.
  • 9Carizza C, Abdelmassih V, Abdeimassih S, et ai. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study[J]. Reprod Bio Med Online, 2008, 17(6): 751-755.
  • 10Busso C, Ferndndez-Sdnchez M, Garcia Velasco J A, et al. The non ergot derived dopamine agonist quinagolide in pre- vention of early ovarian hyperstimulation syndrome in IVF pa- tients: a randomized, double-blind, placebo-controlled trial [J]. HumanReprod , 2010, 25(4): 995 1004.

引证文献10

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部